Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment.
Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment.
复制标题
用阿维A酯治疗重度吸烟者支气管表皮样化生的消退。
DOI：
--
复制
发表时间：
1986
影响因子：
--
通讯作者：
H. Gaget
中科院分区：
文献类型：
--
作者：
J. Misset;G. Mathé;G. Santelli;J. Gouveia;J. Homasson;M. C. Sudre;H. Gaget
选择40名重度吸烟者（每年超过15包）志愿者，并根据根据以下程序确定的化生（IM）指数大于15%完成6个月的etretinate治疗：支气管树10个部位的支气管镜检查和系统活检。将每个活检组织切成10个切片，并计算IM：IM =表皮样化生切片数量/检查切片数量× 100。依维甲酸酯，一种维甲酸衍生物，口服，每日剂量为25毫克，在结束时，患者进行了第二次纤维镜检查协议。对于那些在治疗期间保持吸烟习惯的患者，在治疗6个月后观察到IM的显著降低（P = 10（-5））。此外，在治疗期间停止吸烟并从统计分析中排除的4名患者在第二次纤维镜检查时化生完全消退。没有发病率是由于etretinate或纤维镜检查。依曲替酸盐显著降低重度吸烟者潜在的癌前支气管表皮样化生。它与戒烟的联系可能会诱导支气管上皮迅速恢复正常。
Forty heavy-smoker (over 15 packets per year) volunteers were selected for and have completed a 6-month etretinate treatment on the basis of an index of metaplasia (IM) greater than 15% determined according to the following procedure: bronchoscopy with systematic biopsies in ten sites of the bronchial tree. Each biopsy was cut into ten sections and an IM was calculated: IM = number of sections with epidermoid metaplasia/number of sections examined X 100. Etretinate, a retinoid derivative, was given orally at the daily dose of 25 mg, at the end of which patients underwent a second fibroscopy protocol. A highly significant reduction of IM (P = 10(-5)) was observed after 6 months of treatment for those of the patients who maintained their smoking habits during treatment. Besides, the four patients who stopped smoking while under treatment and are excluded from the statistical analysis all had a complete regression of metaplasia at the second fibroscopy. No morbidity was due to etretinate or fibroscopy. Etretinate significantly reduces potentially precancerous bronchial epidermoid metaplasia in heavy smokers. Its association with smoking arrest may induce a rapid restoration of bronchial epithelium to normal.